Real-world experience of inclisiran prescription at the University of Pennsylvania Health Systems.

Inclisiran is a novel small interfering RNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) that was approved by the US Food and Drug Administration in December 2021. After two doses 3 months apart, it is administered biannually as a subcutaneous injection and has been shown to lower low-density lipoprotein cholesterol (LDL-C) by ∼50% in clinical trials. Here, we present real-world data on the prescription and administration of inclisiran at the University of Pennsylvania Health Systems. Over a 2-year period, there were 243 patients who were prescribed inclisiran, of whom 153 were approved by insurance and initiated therapy. Approved patients were disproportionately Medicare enrollees and more likely to have a history of atherosclerotic cardiovascular disease (ASCVD). Mean post-treatment LDL-C for patients who received at least two doses was 74.7 ± 45.6 mg/dL. For patients new to PCSK9-targeted therapy, a reduction in LDL-C of ∼50% was observed after initiating inclisiran, supporting clinical trial results. 60% of patients with ASCVD achieved an LDL-C level of < 70 mg/dL after adding inclisiran.